The design of metal-based anticancer drugs was initiated by cisplatin (cis-Pt(NH3)2Cl2), one of the leading agents in clinical use with a high cytotoxic effect upon a variety of tumour types, in particular against testicular, ovarian, head and neck, and bladder carcinomas, as well as lymphoma.
.